NEW YORK, Nov 21 (Reuters) - Aggressive marketing of Merck & Co.'s (MRK.N: Quote, Profile, Research) new first-in-class diabetes drug Januvia has led to a strong launch, according to data compiled by ImpactRx Inc., a market research company that tracked new prescriptions written and free samples dispensed. >>> Discuss This Story
